Fig. 7: SerBut does not impact immune responses to vaccination compared with FTY720. | Nature Biomedical Engineering

Fig. 7: SerBut does not impact immune responses to vaccination compared with FTY720.

From: A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice

Fig. 7

a, Experimental schema. Mice were orally gavaged with PBS, SerBut (twice daily, 25 mg per dose) or FTY720 (once daily, 0.02 mg per dose) starting on day −3 until the end of the experiment. On day 0, mice were immunized subcutaneously in the front hocks with 10 μg endotoxin-free OVA, 50 μg alum and 5 μg MPLA. b,c, Mice were bled on day 9 (b) and day 13 (c), and plasma was analysed for anti-OVA IgG antibodies. d–i, Representative flow cytometry dot plots of CD19+B220+ (d,e), CD4+ (f,g), and Foxp3+CD4+ T cells (h,i) in the spleen, along with their respective percentages of the parental cell population (d,f,h), or of the total live cells (e,g,i). n = 5 mice per group. Data represent mean ± s.e.m. Statistical analyses were performed using one-way ANOVA with Dunnett’s post hoc test. P values less than 0.05 are shown.

Source data

Back to article page